Morgan Stanley
NEPH icon

Morgan Stanley’s Nephros NEPH Stock Holding History

Morgan Stanley’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Buy
128,915
+18,000
+16% +$58.5K ﹤0.01% 5591
2026
Q1 		$331K Buy
110,915
+92,956
+518% +$371K ﹤0.01% 5673
2025
Q4 		$87.6K Buy
17,959
+16,044
+838% +$82K ﹤0.01% 6254
2025
Q3 		$9.06K Hold
1,915
– – ﹤0.01% 6928
2025
Q2 		$7.83K Sell
1,915
-3,508
-65% -$9.37K ﹤0.01% 6921
2025
Q1 		$9.33K Hold
5,423
– – ﹤0.01% 6823
2024
Q4 		$7.97K Hold
5,423
– – ﹤0.01% 6880
2024
Q3 		$9.27K Hold
5,423
– – ﹤0.01% 6739
2024
Q2 		$11.4K Hold
5,423
– – ﹤0.01% 6630
2024
Q1 		$11.9K Sell
5,423
-62,125
-92% -$197K ﹤0.01% 6648
2023
Q4 		$234K Buy
67,548
+52,256
+342% +$114K ﹤0.01% 5884
2023
Q3 		$22.6K Hold
15,292
– – ﹤0.01% 6440
2023
Q2 		$23.7K Hold
15,292
– – ﹤0.01% 6512
2023
Q1 		$16.4K Hold
15,292
– – ﹤0.01% 6695
2022
Q4 		$17.7K Hold
15,292
– – ﹤0.01% 6733
2022
Q3 		$14K Sell
15,292
-2,962
-16% -$4.19K ﹤0.01% 6953
2022
Q2 		$28K Buy
18,254
+10,729
+143% +$29K ﹤0.01% 6854
2022
Q1 		$33K Buy
7,525
+1,049
+16% +$4.98K ﹤0.01% 6902
2021
Q4 		$38K Sell
6,476
-7,361
-53% -$53.7K ﹤0.01% 6933
2021
Q3 		$121K Buy
13,837
+9,004
+186% +$78.1K ﹤0.01% 6264
2021
Q2 		$49K Buy
4,833
+1,018
+27% +$8.49K ﹤0.01% 6685
2021
Q1 		$25K Hold
3,815
– – ﹤0.01% 6646
2020
Q4 		$33K Hold
3,815
– – ﹤0.01% 6289
2020
Q3 		$28K Hold
3,815
– – ﹤0.01% 5935
2020
Q2 		$32K Hold
3,815
– – ﹤0.01% 5849
2020
Q1 		$24K Buy
+3,815
New +$32.4K ﹤0.01% 5743

Other funds holding NEPH

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Morgan Stanley's NEPH Position: Q2 2026 in Review

Morgan Stanley increased its Nephros (NEPH) stake by 16% in Q2 2026, buying an estimated $58.5K and bringing the position to 128,915 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #5591.

Morgan Stanley first reported a position in NEPH in Q1 2020 and has held it in 26 quarters since. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Morgan Stanley held 128,915 shares of Nephros worth $460K as of Q2 2026.
  • Morgan Stanley bought 18,000 Nephros shares in Q2 2026, an estimated $58.5K.
  • Nephros made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5591 holding.
  • Morgan Stanley first reported a position in Nephros in Q1 2020 and has held it in 26 quarters since.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.